Introduction
All cases of malignant disease in the Royal Air Force are reported to a central registry at the Central Medical Establishment, progress and follow-up reports being regularly furnished for each case. Review and follow-up clinics are held at Uxbridge once a month for patients who have completed hospital treatment. Special meetings are held at regular intervals between the surgeons, pathologist and Officer Commanding, Hospital. We then discuss methods of treatment used over the past few months, recent advances in technique and any other problems arising in this particular unit.
The treatment of malignant disease by chemotherapy has necessitated the supply of highly specialized equipment, which my colleagues will describe, but each individual case brings differing problems, that can only be solved by a team working together.
In 1961 we reviewed all cases of Hodgkin's disease and testicular tumours recorded between the years 1940-1960. In the Hodgkin's group we found a total of 175 cases reported but only 143 were of statistical value. Our object was to assess the five-year survival rate in those treated by irradiation, and those treated by irradiation plus chemotherapy. The cytotoxic drugs used in these early cases were firstly nitrogen mustard (HN2) and later mannomustine. We found that our five-year survival rate was about 38%, both for those treated by irradiation alone, and those receiving chemotherapy in addition to irradiation.
Of course a large number of those receiving irradiation only were those cases recorded prior 56
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Clinical and Pathological Aspects of Cancer Chemotherapy to the use of cytotoxic drugs. The pathological department at the same time reviewed all the histological slides of Hodgkin's disease, and they, from a purely histological forecast, arrived at a five-year survival rate of 46 % for the total series.
Our review of testicular tumours over the same twenty-year period comprised a total of 169 recorded cases, but again only 140 are assessed statistically. I cannot help but stress the point which became so obvious in these investigations, that one small detail missing from clinical notes made them valueless. In this series again we remember the fact that the overall age group is low compared to similar records of civilian cases. We found an average age incidence of 26 years (teratoma) and 29 years (seminoma). The relative incidence of the two types of tumour we found to be seminoma 55 % and teratoma 45 %. Maldescent of the testis in this series was found to have a real relationship with the incidence of neoplasia. We found in our total of 140 cases that 8 5% had suffered from maldescent of the same testis.
Our five-year survival rate was seminoma 65 % and teratoma 54 %. These figures are assessed on Stage I cases, i.e. presenting with no evidence of metastases. All Stage I patients are treated by the conventional method of simple orchidectomy plus irradiation to the internal iliac and para-aortic glands. Treatment of pulmonary as opposed to mediastinal metastases has been with cytotoxic drugs, e.g. methotrexate, but on the whole results have been disappointing, with temporary improvement only.
Advance in the treatment of testicular tumours over the years is, however, very real. The great improvement in results following simple orchidectomy plus irradiation is obvious when compared with results of the radical operation or simple orchidectomy alone. The Cinical Aspects of Cancer Chemotherapy It is my intention to present some practical aspects of the chemotherapy of malignant disease as carried out at the Royal Air Force Hospital, Uxbridge.
Because of the encouraging results of cytotoxic therapy reported in the world literature we originated a Special Chemotherapeutic Unit for the Treatment of Uninhibited Malignancy and called it SCUTUM (lat. a shield).
This unit is run by surgeons and pathologists working in close collaboration and together they fully assess each patient's case before any cytotoxic drug is given.
The main purpose of SCUTUM is the effective practical control of malignant disease whilst at the same time protecting the patient's normal tissues from the adverse effects of the chemotherapeutic agents.
Four general types of anti-cancer agents have proved of therapeutic value to date. They are alkylating agents, antimetabolites, cell poisons and hormones. All of these have been used by us and illustrative examples will be given later. Our aim is to administer the optimum dose of the most suitable drug without prejudicing the patient's recovery by producing bone marrow aplasia, irreparable liver damage, or severe gastrointestinal disturbance.
All-cases of malignant disease sent to the Royal Air Force Hospital, Uxbridge, are considered by the special unit and are placed in one of four groups: those patients who will receive cytotoxins as a prophylactic measure; those patients who will receive cytotoxins in full therapeutic doses; those patients who should have prophylactic bone marrow removal and storage during a remission; and those patients who are to have conventional surgery and radiotherapy without the concommitant use of cytotoxins.
Cytotoxins are given prophylactically because it is known that malignant cells appear in the peripheral circulation during the course of operations for malignant disease (Engell 1955 , Moore et al. 1957 , and these drugs provide a specific method of attacking potential metastases. For example, we always give 300 to 500 mg mannomustine intravenously in 3 or 5 doses of 100 mg during such operations as biopsy of suspected tumours or ablative procedures like radical mastectomy. There is proved reduction in the number of circulating malignant cells when these measures are adopted (Roberts & Cole 1958 , Cruz et aL. 1956 ). Hiematopoietic depression is slight in patients who have not had previous irradiation or chemotherapy. Only a long follow up of recurrence rates in the various stages of the several malignant diseases will prove the efficacy of the prophylaxis.
The administration of therapeutic doses of cytotoxins depends on whether they are to be used alone or in conjunction with either radiotherapy or surgery. We believe that full therapeutic courses can only be properly controlled in hospital. The choice of treatment must be determined by the structures involved, the presence or absence of metastases or constitutional symptoms, and the histology of the tumours. Patients with early malignant disease should theoretically require less of a chemotherapeutic agent than those with advanced disease, but because of the difficulty in monitoring tumour response in early cases we give the maximum tolerable dose in an attempt to ensure the maximum tumour control.
Every case of malignancy which is considered for anti-cancer drugs is placed in one of the classes shown in Table 1 which has been devised by us to correlate the state of the patient with the effects of therapy upon the disease process. The treatment of cancer involving the use of cytotoxic drugs depends on several broad principles. Firstly, individual consideration of the patient must be undertaken as each small detail of the case influences the choice of drug and its method of administration. Secondly, the expectation of life without treatment should be at least two months to permit adequate dosage and therapeutic response, but palliative chemotherapy may be undertaken to alleviate distressing symptoms in late cases. Thirdly, the advantages to the patient must be offset against the risks of permanent damage to the hematopoietic system or liver.
At our unit the surgeon and pathologist carry out pre-treatment planning for all patients who are to be given cytotoxic drugs. The patient's history and treatment are recorded in special case notes along with the Class (Table 1) , full blood count, ABO group, genotype and liver function tests. Any relevant pathological examinations such as a quantitative Hogben or urinary chorionic gonadotrophins for cases of chorion carcinoma are done and repeated during therapy to evaluate treatment.
As the normal hamatopoietic system is most vulnerable to the anti-cancer agents we give careful consideration to the advantages of removing, processing and storing the patient's bone marrow at -75°C prior to treatment. We have been encouraged by the hxematological response to giving back autologous marrow to patients who have bone marrow depression and this enables us to give several courses of treatment.
In addition to autologous bone marrow storage we are preparing and storing feetal hematopoietic tissue which is fully genotyped and may be used to cover cases whose own marrow is unsuitable (Kay & Constandulakis 1959), for example, cases of Hodgkin's disease, lymphosarcoma, poor marrow reserve following irradiation or cases7 in which the marrow is already involved with metastatic tumour cells. In pre-treatment planning, therefore, bone marrow samples are examined for tumour cells and hematopoietic potential.
Methods of monitoring the effect of the drugs upon the particular disease process are determined prior to therapy because we consider it essential to know early in treatment if the tumour is susceptible. Clinical and biochemical methods, radiology and radioisotopes or a combination of these are used to determine tumour response.
Last in pre-treatment planning comes the choice of drug, and this is based at present on experience with a drug for a particular tumour type, but the not altogether theoretical consideration that all anti-cancer agents act at the metabolic enzyme level is constantly borne in mind and correlation of the biochemical pathways in cells and drug structure are determining factors. Dosage is predetermined and is related to body weight and tumour size. Liver damage or marrow depression may preclude the administration of adequate amounts of drug. Gross tumours very often do not respond to systemic drugs in any quantity.
Not all anti-cancer agents can be given orally but alkylating agents like chlorambucil, phenylalanine mustard, and cyclophosphamide and the antimetabolites methotrexate and 6-mercaptopurine are used by us as maintenance drugs for outpatients who have already had a full inpatient therapeutic dose of any one of them. We ensure that these patients are reviewed at least once a week and readmit any patient who shows sign of marrow depression or has any untoward symptom. The nausea produced by oral cytotoxins can be readily overcome with promethazine theoclate or chlorpromazine.
Methotrexate is extremely toxic for the gastrointestinal mucosa and we have experience of lesions in different patients in the mouth, stomach, ileum, cacum and colon.
Intravenous administration of cytotoxins ensures a more adequate blood level of the drugs. We have given the alkylating agents in divided doses to a total predetermined amount and we have given the same amount diluted in isotonic solutions by continuous infusion. The nausea, vomiting and anorexia caused by the former method are obviated by the latter. Moreover, twice the ordinary daily dose is readily tolerated over twenty-four hours. For example, 100 mg mannomustine in 20 ml water injected intravenously causes nausea and vomiting whilst 200 mg mannomustine given by continuous intravenous infusion in 2 litres of saline does not. The hoematopoietic depression produced by both methods is similar. We find the continuous infu. sion method ideal for such conditions as Hodgkin's disease and lymphosarcoma, the clinical response being excellent with minimal side-effects.
In our experience it is safer to give the antimetabolites, methotrexate, N-desacetyl-thiocolchicine and vinblastine sulphate intravenously in divided doses as the toxic manifestations on all tissues are very marked when a continuous infusion method is used. Haematopoietic depression and gastrointestinal mucosal lesions occur readily with intravenous methotrexate. It is our practice to modify the dose so that continuous treatment may be undertaken; cessation of treatment because of side effects, whilst allowing rapid recovery of the bone marrow and alimentary tract, leads in our experience to tumour progression and a resistant growth.
We have given a combination of antimetabolites and alkylating agents intravenously in an attempt to control florid malignant disease. As an example, in a patient with rapidly growing pulmonary metastases from a terato-carcinoma of the testis, we gave 50 mg methotrexate by continuous infusion over a period of six hours followed by 2,000 mg mannomustine during the ensuing twenty-four hours. Doses of this magnitude require continuous narcosis with pethidine, promethazine and chlorpromazine whilst treatment is in progress. Constant supervision and monitoring of the effects of the drugs by a continuous electrocardiographic tracing enables us to stop treatment should this be necessary at any time. We have noted diminution and absence of the T wave in several patients towards the end of treatment. Short-term, large-dose treatments of this kind have resulted in abeyance of the radiological appearances of the pulmonary metastases, hkmorrhages into multiple metastatic melanomata and disappearance of a metastatic buttock deposit from an adrenal carcinoma.
We have used the intra-arterial method of introducing chemotherapeutic agents as an adjunct to surgical ablation of malignant disease. Where possible the major arteries supplying the region undergoing surgery are cannulated and the field of operation perfused before any manipulation is undertaken; 5 % fluorescein is run into the cannulated vessels and the area of fluorescence is observed under ultraviolet light. Whilst the standard radical operation is in progress a predetermined dose of an alkylating agent is run into the cannulated arteries at the same pressure as the fluorescein infusion thus perfusing the affected organ and its lymphatic drainage. Examples of this are perfusion of the pectoral region during radical mastectomy by way of the internal mammary artery and axillary artery, retrograde perfusion of the parametrium by way of the uterine arteries during the early stages of Wertheim's hysterectomy and of the thigh via the external iliac artery during block dissection for malignant melanoma. In addition to these perfusions mannomustine is administered prophylactically, but the overall dose is modified. A reduced dose is also given when the patient is to undergo post-operative irradiation.
The topical application of cytotoxins is limited but we have given methotrexate directly on to a recurrent radio-resistant buccal carcinoma in which the regional lymphatic glands were involved and fixed to the carotid sheath. A combination of topical, oral and intravenous methotrexate produced arrest of the disease.
We have successfully stopped the hvmaturia due to invasion of the bladder by adenocarcinoma of the colon by introducing triethylene thiophosphoramide into the bladder by means of a catheter in doses of 10 mg in 200 ml saline for one hour on five successive days. This patient received at the same time a full course of N-desacetylthiocolchicine intravenously.
In our experience intraperitoneal and intrapleural application of alkylating agents limits the rate of formation of malignant effusions. The longest remissions are obtained after paracentesis. Involvement of the serous cavities by malignant disease is of such serious prognostic significance that only palliative doses should be given by this route.
Every patient receiving cytotoxins has daily full blood counts charted graphically. Barrier nursing in cubicles is instituted in patients whose total white cell counts fall to below 1,500 per c.mm. Wide-spectrum antibiotics are given if the count falls to 1,000 per c.mm or less. Fresh platelet pack blood transfusions from our own donor panel are used for thrombocytopenia. Intravenous autologous bone-marrow replacement is undertaken in patients whose marrow recovery is slow after treatment and who will need further chemotherapy. Careful and frequent clinical examination of all patients receiving cytotoxins enables us to discontinue a drug should its toxic effects become serious. Blood transfusion is used frequently during treatment. Patients who are receiving steroids for any reason need increased doses during cytotoxic therapy and need regular serum electrolyte estimations and blood pressure recordings.
Clinical evaluation is used in every patient when diminution in size of visible or palpable tumours may be assessed. Improvement in the patient's general condition often accompanies satisfactory tumour response. For example, in acute Hodgkin's disease the temperature falls to normal and the constitutional symptoms abate. Certain of the alkylating agents give a general feeling of well-being to the patient. Subjective improvement is to be welcomed in patients but does not necessarily mean there is regression of disease.
Regular radiological examination of pulmonary metastases whilst treatment is in progress will show if the drug is having any effect. We perform weekly radiographs on patients with a lesion detectable by this method. Radiological assessment of bony metastases often shows little change but loss of pain associated with these lesions indicates a good response to treatment.
Biochemical tests under certain circumstances indicate whether the drug is having a beneficial effect. For example, we have had improvement in liver function in a patient with hepatic metastases from a hypernephroma treated with methotrexate and cyclophosphamide, the alkaline phosphatase falling from 57 to 20 King-Armstrong units.
If the tumours are superficial we give radioactive phosphorus (32p) intravenously and estimate 32P activity in the tumour related to the normal surrounding skin using a collimated end window counter. This is repeated soon after commencement of treatment when diminution in 32P activity indicates a response to therapy (Hale 1961) .
We would like to stress that the effective control or otherwise of tumour growth should be determined as early as possible in treatment by one or more of the monitoring methods so that an ineffective drug can be stopped and another substituted before marrow depression precludes further immediate treatment.
It is our experience that the carefully controlled practical application of experimental chemotherapeutic studies to human cancer shows that some malignant diseases can be controlled for a limited period. The judicious use of those agents which are known to possess anti-cancer properties should enhance the efficacy of conventional methods of treatment without proportionately increasing the risks.
Meticulous planning of treatment and daily assessment of its effects necessitates close liaison between surgeon and pathologist.
Flight Lieutenant T J Betteridge (Royal Air Force Hospital, Uxbridge)
The Pathological Aspects of Cancer Chemotherapy
In the treatment of advanced malignant disease, and in our efforts to minimize the occurrence of metastases in the early stages of cancer spread, we have found it essential to have the closest possible liaison between the operating theatre, the ward and the laboratory. It cannot be over-emphasized that this co-operation commences when a patient is first considered for treatment. Investigations help to show fully the extent of disease progress and enable treatment to be modified from case to case. For every patient we must know as much as possible about heematopoiesis and hepatic function in particular, since it is these systems that are most at risk when cytotoxins are administered. With regard to hematopoiesis we need to know three things: Whether metastases are present in the marrow, whether the patient is likely to withstand treatment by cytotoxins in full dosage, and whether the bone marrow is suitable for storage.
A bone marrow biopsy is carried out in each case. The iliac crest is used for preference since a good sample can be obtained and we have found that the patient who has experienced sternal puncture finds the former site less painful when negative pressure is applied to the marrow cavity. Direct smears are examined for normal erythropoiesis, myelopoiesis and the presence of malignant cells.
Buffy layer preparations are also examined to exclude tumour deposits since large numbers of cells can be easily scanned by this method. When all formative elements are normal and no malignant cells are demonstrated, the marrow is considered suitable for storage; the initial course of cytotoxins can then be administered in full dosage without undue risk of prolonged agranulocytosis, thrombocytopenia or persistent anmmia.
The presence of hypoplasia or disturbance of maturation will lead us to commence with a lower initial dosage until the response of the patient to treatment can be evaluated by the peripheral blood picture. Such marrow may be unsuitable for storage; in one patient who had hypoplastic marrow following irradiation, aspiration was performed in spite of a poor biopsy specimen and an extremely low yield was obtained. Where malignant cells are identified in marrow smears we consider it unsuitable for storage. It has been suggested (Newton etal. 1959 ) that the presence of a few malignant cells may not matter, but we feel that the possibility of seeding the patient's lesions in new and possibly more dangerous sites must be completely ruled out. A full blood count including reticulocytes, platelets and absolute values is performed in each case. Anwmia must be corrected by blood transfusion before the start of treatment, although in some cases we have found the anemia to improve when the disease has been controlled. The presence of an initial severe anaemia or of thrombocytopenia does not contraindicate treatment but may well influence the choice of drug.
Liver Function Tests
Certain tests such as serum transaminase and serum bilirubin are carried out in order to establish normal levels for the patient. The alkaline phosphatase is estimated and, in conjunction with the bromsulphthalein excretion curve and the flocculation and turbidity tests, provides a valuable means of estimating hepatic function and the likelihood of metastases where these are not clinically apparent. The plasma protein levels are estimated and an electrophoretic curve obtained.
Other Tests
The urine is routinely screened for protein and the presence of cells. In cases of malignant disease affecting the renal tract blood urea estimations and renal function tests are performed.
Patients with malignant melanomatosis are screened for the excretion of melanogens which may disappear later during the course of treatment. Those patients who have testicular or chorionic tumours have their urinary gonadotrophins assessed and these, with quantitative Hogben tests, are extremely useful in following the progress of the disease.
The Maintenance ofPatients During and After Treatment
During the course of full treatment with cytotoxic drugs a visual record must be kept of the effect of the drugs on the patient's hwmatopoietic system, and therefore a chart is maintained which shows at a glance the drug or drugs being given and the state of the patient's peripheral blood. During therapy estimations are normally carried out daily. or on alternate days depending on the intensity of treatment. We have found with some dru-gs that it is necessary to continue to follow up the peripheral blood picture for up to six weeks after treatment has finished, whereas with others the depression of hamatopoiesis is more rapid in onset. Figs 1 and 2 show comparative charts of the rate and duration of hemoglobin fall and the trend of the total white cell count in patients undergoing full treatment with different drugs. With mannomustine there is a prolonged and persistent fall of hemoglobin after treatment has stopped, and a similar lengthy depression of the total white cell count (Fig 1) . With cyclophosphamide treatment usually lasts longer; there is a more gentle slope of hemoglobin fall and the white cell count returns towards normal rather more quickly after treatment has finished (Fig 2) . With methotrexate there is a steep fall of hemoglobin similar to that seen with mannomustine but a much more rapid return to normal of the total white count after treatment has finished.
The rate of fall of hemoglobin and the degree of depression of the white cell count is greater when cytotoxins are given in combination, but the effect of drugs combined is not as great as might be expected from consideration of the effects of the same drugs used alone.
The charts give an indication of the way in which patients have reacted to a full course of a particular cytotoxic drug. We have found that although there has been some variation in dosage the majority show a similar pattern of response. No patient, however, is predictable. Somewillhave no depression of note with quite a large dose whilst others may have a severe depression on much smaller doses. For this reason when drugs I 5d I' 16 I c are administered by continuous intravenous infusion estimations are carried out daily. Our hmmatological values are obtained from capillary blood as far as possible, to obviate frequent venepuncture.
Wherever possible transfusion is carried out on those patients whose heemoglobin level falls below 70 %. We use fresh blood from our own donor panel in patients with purpura or thrombocytopenia without bleeding; fortunately occurrences of this type have been infrequent.
When the white cell count of a patient falls below 1,500 for more than twenty-four hours we have instituted barrier nursing. The incidence of infections has been extremely low with cubicle nursing and a good understanding by the nursing staff of the needs of the patient during this time. Case 1 (Fig 3) A patient with generalized Hodgkin's disease treated with a continuous infusion of mannomustine. The degree of depression of all elements produced by mannomustine in this type of treatment is extremely predictable. continued after there was evidence of depressed htmatopoiesis because of the good clinical response and the knowledge that recovery after smaller doses was relatively rapid. She later received another course of treatment with benefit, and received 17-9 g in all. Her marrow recently became hypoplastic with a falling htmoglobin and persistently low white cell counts after therapy had been discontinued. One half of her stored marrow (at -79°C) was returned after reconstitution, with an almost immediate reticulocytosis and a later rise in white cell count, but it is as yet too early to determine the degree of benefit. Case 3 ( Fig 5) This patient received radiotherapy for a squamous cell carcinoma of the buccal cavity with regional node involvement. Treatment was with methotrexate topically, orally and intravenously. Comment: There was a sharp fall in polymorphs (A) and a slow drop in hemoglobin. The platelets were temporarily quite low. On a reduced dosage there was a swift return to normal (B) and a good reticulocyte response. A second dip (C) was probably due to the cumulative effect of the treatment, with a steady fall in reticulocytes and the commencement of a fall in heamoglobin levels.
Case 4 ( Fig 6) This patient had previously been successfully treated with methotrexate for pulmonary metastases from a chorion carcinoma of uterus. The course of vinblastine sulphate was given for hepatic metastases. Comment: This patient characteristically had a severe anxvmia when the disease was active, as shown in the first part of the chart (A). Intensive treatment caused a sharp and severe fall in polymorphs which was of short duration (B). The hemoglobin level commenced to rise although the reticulocyte level remained fairly constant. The platelet level also rose. This improvement in heemoglobin and platelet levels has been noted in other cases treated with this drug. The reticulocyte count then began to drop (C) and at the same time the disease again became active with a fall in hemoglobin.
There was a rise in lymphocytes which for a short time again became the dominant cell. When this patient was readmitted after her first course of treatment with methotrexate, before the hepatic metastases were apparent, she presented with lethargy and depression. On investigation she had a macrocytic anemia. Examination of her bone marrow at this time showed an early megaloblastic picture and erythroid hyperplasia. Folic acid was estimated and found to be absent. Other patients on methotrexate have also shown a gradual increase in red cell size.
The value of the charts in presenting the treatment and hematological picture together cannot be over-emphasized. The large number of investigations may at times seem tedious but is essential. The total white cell count, for example, can fall by up to 80 % of its previous level within twenty-four hours; and the platelet level may also fall abruptly at any time during treatment.
Liver function tests are repeated during and after treatment. The transaminase and serum alkaline phosphatase levels have given us much useful information upon the state of progress of the disease during and after treatment, and are of value in monitoring the susceptibility of the tumour to the drug being used. A return towards normal values may occur before there is clinical improvement.
That autologous bone marrow can prevent the effects of radiation in animals (Barnes & Loutit 1954 ) is well recognized. In the 'massive dosage' regime with cytotoxins autologous marrow has (Clifford et al. 1961) . Homologous marrow has been protective in cases of severe radiation damage in man and there is unquestionable evidence of prolonged survival of homologous marrow following treatment with cytotoxins (Beilby et al. 1960 ). Reports on the replacement of autologous splenic tissue in man and on the protective role of thoracic duct lymphocytes in rats indicate that the use of splenic tissue may become important as an adjunct to autologous marrow or as an alternative, since malignant deposits are rarely found in the spleen in metastatic carcinoma.
The emphasis, in our consideration of the protective role of autologous marrow in patients treated with cytotoxins, has been shifting from the prevention of the consequences of acute marrow disruption following massive near lethal doses to the maintenance of an efficient marrow despite several treatments possibly spread over a year or longer. As chemotherapy becomes steadily more successful this problem will arise more frequently.
Autologous bone marrow can be extremely useful in the treatment of patients with severe marrow hypoplasia which may develop during repeated or lengthy courses with cytotoxins. Two of our recent cases have had autologous marrow returned with encouraging results. The immediate and striking reticulocytosis in one of these revives interest in the postulate that a humoral factor, first considered over ten years ago (Jacobson 1952) , may also be acting to restore the functional capacity of the damaged marrow. The use of autologous marrow has enabled us to give further beneficial treatment which otherwise would not have been possible. There is thus a dual role for autologous marrow; in treatment with massive doses of cytotoxins and when the long-term effects of cytotoxins have become manifest. We believe that storage of autologous marrow should be carried out in patients who already have metastases elsewhere and who may later need chemotherapy or radiotherapy. If storage is not carried out at this stage 'later' can often mean 'too late' with marrow metastases then present. It would be ideal to store marrow before metastases have occurred but viability after eighteen to twentyfour months at -79°C appears much reduced. Results of storage with liquid nitrogen appear much more promising. The status of foetal hmmatopoietic tissue is less well defined and its role has not yet been established. To enable foetal or homologous marrow to be used if necessary, all patients are genotyped when they are first considered for treatment.
The big problem at present is the selection of the right drug for each individual tumour. With the possible exception of tumours of the reticuloendothelial system it is impossible to predict susceptibility in most cases unless an immediate monitoring system is applicable.
A preliminary report on tissue culture methods (Ambrose et al. 1962 ) has encouraged us to continue work on a direct in vitro method of assessing tumour drug sensitivity.
The pathologist will be concerned to identify malignant cells in blood samples taken at operation and in pleural or ascitic fluid since this information will directly affect prognosis and treatment.
There is no doubt that the proper application of. knowledge derived from the laboratory in combination with the skill of clinicians can do a great deal to alleviate the conuitiun of the patients suffering from uninhibited malignant disea,re. We are also hopeful that the work on the prevvntion of metastases in those cases receiving cytotoxins before, during and after operation will be effective. Early reports of chemotherapy combined with operation are encouraging (Denk & Karrer 1961) .
It has been our intention to try and present the picture of a practical unit which attempts to serve the needs of each individual patient within the context of his disease. It would not be right and proper to give potentially toxic or lethal drugs unless we are convinced that real benefit can result without imposing suffering and misery and we believe that we are able to do this.
We hope that we have been able to show that the administration of cytotoxins is not akin to sorcery but is a logically planned and controlled therapy which gives the patient the opportunity of an extended, useful and pain-free life.
